Scleroderma News and Research

Latest Scleroderma News and Research

Fudan, UTHealth introduce international network to fight against scleroderma

Scleroderma clinicians and researchers in the United States and China have launched an international network to fight this debilitating disease that affects more than one million people worldwide.

24 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) applauds the joint statement issued by the American Thoracic Society for the first evidence-based clinical guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). The guidelines represent progress in understanding of the disease and a milestone for patients. The devastating and deadly disease also called simply "Pulmonary Fibrosis" or "PF" has no FDA approved treatment and no cure.

18 Mar 2011

Treatment with sildenafil significantly reduces RP in patients with scleroderma

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud's phenomenon in patients with limited cutaneous systemic sclerosis, also known as scleroderma.

8 Mar 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).

4 Feb 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test. The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.

9 Nov 2010

New iPSC cell lines could help in treating patients with lung diseases

A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could possibly lead to new treatments for these debilitating diseases.

29 Oct 2010

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

29 Oct 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

Amira submits IND application for AM152 antagonist

Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

28 Sep 2010

New federal funds to create first national patient registry for pulmonary fibrosis

During the 8th annual National Pulmonary Fibrosis (PF) Awareness Week, Sept. 11 to 18, the Coalition for Pulmonary Fibrosis (CPF) met with over 45 legislators, both Representatives and Senators, and as of this date there are 139 House co-sponsors for the Pulmonary Fibrosis Research Enhancement Act (PFREA) to fund research on this deadly disease.

24 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Researchers to conduct gene analysis for ankylosing spondylitis

A new study designed to test suspected links between genes and two immune disorders could open the door to better ways to diagnose and treat the conditions that affect a combined total of approximately 2.5 million people in the United States, report scientists at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2010

Scleroderma News and Research

Latest Scleroderma News and Research

Fudan, UTHealth introduce international network to fight against scleroderma

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

Treatment with sildenafil significantly reduces RP in patients with scleroderma

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Special Surgery investigators to present future of clinical care at ACR annual meeting

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New iPSC cell lines could help in treating patients with lung diseases

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Amira submits IND application for AM152 antagonist

New federal funds to create first national patient registry for pulmonary fibrosis

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Researchers to conduct gene analysis for ankylosing spondylitis

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scleroderma News and Research

Latest Scleroderma News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in